Relmada Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Relmada Therapeutics, Inc. has undergone a significant strategic shift, terminating prior drug programs to focus on two new clinical-stage candidates, NDV-01 and sepranolone, while securing substantial new financing.
NASDAQ
10-K: Relmada Therapeutics Announces Strategic Shift in Annual Report, Focuses on New Drug Candidates
Relmada Therapeutics' 10-K filing reveals a strategic shift towards new drug candidates after disappointing trial results, emphasizing pipeline diversification and cost-effective development.
NASDAQ
Relmada Therapeutics, a clinical-stage biotech company, reported its 2023 annual results, highlighting progress in its esmethadone and psilocybin programs, while also noting significant financial losses.